Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2

Status

Completed 129Recruiting 59Terminated 44Active not recruiting 44Unknown 13Withdrawn 6Not yet recruiting 5Enrolling by invitation 1

Sponsor Class

INDUSTRY 3OTHER 1FED 1

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Genitourinary 4

Conditions

Prostatic Neoplasms 3mCRPC 1Neoplasm Metastasis 1Advanced Prostate Cancer 1Adenocarcinoma 1

Interventions

Cisplatin 122Carboplatin 120Drug Therapy 104Bevacizumab 101Capecitabine 96Oxaliplatin 95Radiotherapy 92Gemcitabine 88Paclitaxel 87tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 66Magnetic Resonance Spectroscopy 63Fluorouracil 61sintilimab 58Injections 57anlotinib 51Docetaxel 51Surgical Procedures, Operative 48130-nm albumin-bound paclitaxel 48fludarabine 45Pemetrexed 43Standard of Care 42Biopsy 42venetoclax 41Irinotecan 41lenvatinib 40Leucovorin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × enzalutamide × Clear all
NCT07592910 2026-05-18

MOMENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Not yet recruiting
60 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT07198633 2025-09-30

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
212 enrolled
Genitourinary

Advanced Prostate Cancer

NCT07104110 2025-08-05

Study of QLH12016 in Combination With Novel Hormonal Agent in Subjects With Advanced Prostate Cancer

Qilu Pharmaceutical Co., Ltd.

Phase 1/2 Not yet recruiting
50 enrolled
Genitourinary

Prostatic Neoplasms

NCT07104643 2025-08-05

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

TYK Medicines, Inc

Phase 1/2 Not yet recruiting
48 enrolled

mCRPC

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡